Clinical Trial Update: DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer [Phase 3]

View source ↗

Summary

This is a Phase III clinical trial evaluating trastuzumab deruxtecan with either rilvegostomig or pembrolizumab as first-line therapy for HER2-expressing, pMMR …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Rilvegostomig (rilvegostomig)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Endometrial Cancer | Phase 3 | Status: RECRUITING